NetworkNewsBreaks

TuesdayNov 02, 2021 11:15 am

NetworkNewsBreaks – Net Element Inc. (NASDAQ: NETE), Mullen Automotive Showing Commitment ‘To Be Part of the Rising Electric Era of EVs’

Mullen Automotive Inc., an emerging electric vehicle (“EV”) manufacturer, which previously announced a definitive stock-for-stock reverse merger agreement with Net Element (NASDAQ: NETE) in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger company, today announced that Mullen Automotive has begun its plans to expand on its 100-acre site in Robinsonville, Mississippi. Located in Tunica County, Robinsonville is approximately 40 miles south of Memphis, Tennessee. Mullen’s Advanced Manufacturing and Engineering Facility (“AMEC”) currently occupies 124,000 square feet of manufacturing space. With over 100 acres of total available land on the property, Mullen is moving ahead…

Continue Reading

TuesdayNov 02, 2021 11:04 am

NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Submits IND Application to Evaluate Clinical Candidate in Phase 2a Trial in Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) to evaluate its clinical candidate, TRP-8802, in a phase 2a clinical trial. Conducted with Kevin Boehnke, Ph.D. from the University of Michigan, the trial seeks to investigate safety and preliminary effectiveness of psilocybin-assisted therapy among patients with fibromyalgia in collaboration with the University of Michigan and will evaluate the company's oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy.…

Continue Reading

TuesdayNov 02, 2021 10:32 am

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Schedules R&D Briefing to Release Breakthrough Research Findings

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, will be hosting an in-person and virtual research and development briefing. Scheduled for Nov. 8, 2021, from 8:30–9:30 a.m. EST, the briefing is slated to include breakthrough preclinical, research findings that indicate advancements in the company’s focus on creating a promising approach for patients in need of effective and safe prescription therapies in the mental health space. Cybin CEO Doug Drysdale and other key members of the company’s senior scientific research team will be hosting the event, which will be held during the Wonderland Conference in Miami;…

Continue Reading

TuesdayNov 02, 2021 9:59 am

NetworkNewsBreaks – Friendable Inc. (FDBL) to Showcase ShamirMuzik’s Journey with Fan Pass Livestream Platform

Friendable (OTC: FDBL), a mobile technology and marketing company, today announced the addition of ShamirMuzik to its Fan Pass Livestream artist platform. As an affiliate artist of Warner Bros. Entertainment and part of indie label “The MHZ” who has fans, social media followers, streams and a genuine connection with his audience, Fan Pass is preparing to develop a case study specifically around ShamirMuzik, highlighting his journey with the platform. The case study will run through the end of this year and showcase how artists can utilize Fan Pass “Artist Pro” services to enhance their livestreams with custom merchandise, their very…

Continue Reading

TuesdayNov 02, 2021 9:25 am

NetworkNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Releases Entertainment Lineup for Premiere Psychedelic, Wellness Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced the list of entertainers that will be featured during its upcoming Meet Delic event. The event, scheduled for Nov. 6–7, 2021, in Las Vegas, is designed to be an immersive edutainment experience offering everything from pop-royalty dance performers and groundbreaking visual experiences to new technologies and research. The agenda also includes thought-provoking presentations and the world’s largest psychedelic business expo. The event’s entertainment lineup will be offering music, visual technology and performance art and include Little Miss Nasty, a dance…

Continue Reading

MondayNov 01, 2021 2:44 pm

NetworkNewsBreaks – CRA International, Inc. (NASDAQ: CRAI) Featured in Research Note from Sidoti

Earnings Preview CRA International, Inc. (NASDAQ: CRAI) was featured in a company-sponsored research note published by Sidoti & Company, LLC. The headline of the note reads, “We Estimate 3Q:21 EPS Growth Of 21.5%, Led By Positive M&A Activity And Margin Expansion; Our 2021-2023 EPS CAGR Of Over 20% And Strong Free Cash Flow Supports $135 Price Target.” Click here to access the full report. About CRA International, Inc. Charles River Associates[LB1] (R) is a leading global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides…

Continue Reading

MondayNov 01, 2021 2:32 pm

NetworkNewsBreaks – Information Services Group, Inc. (NASDAQ: III) Featured in Research Note from Sidoti

Earnings Preview Information Services Group, Inc. (NASDAQ: III) was featured in a company-sponsored research note published by Sidoti & Company, LLC. The headline of the note reads, “We Forecast 3Q:21 EPS Of $0.05; Strong Industry Demand Trends And Improving Margin Structure Support Our Projected 2021-2023 EPS CAGR Of 27.2%; Maintain $11 Price Target.” Click here to access the full report. About Information Services Group, Inc. ISG (Information Services Group) is a leading global technology research and advisory firm. A trusted business partner to more than 700 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping…

Continue Reading

MondayNov 01, 2021 2:18 pm

NetworkNewsBreaks – Rezolute Inc. (NASDAQ: RZLT) Announces Underwritten Public Offering, Concurrent Registered Direct Offering

Rezolute (NASDAQ: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, has announced the pricing of an underwritten public offering. The offering consists of 6,030,847 shares of its common stock at a public offering price of $6.50 per share and of pre-funded warrants to purchase 1,661,461 shares of its common stock at a public offering price of $6.49 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each pre-funded warrant. Rezolute also announced the pricing of its concurrent registered…

Continue Reading

MondayNov 01, 2021 1:58 pm

NetworkNewsBreaks – InnerScope Hearing Technologies Inc. (INND) to Be Featured in ‘New to the Street’ Broadcast

InnerScope Hearing Technologies (OTC: INND) will be featured in an upcoming segment of FMW Media’s “New to the Street” nationally syndicated program. The company will be one of four that will be featured on New to the Street’s 259th broadcast, airing at 10:30 p.m. PT on Fox Business Network on Monday, Nov. 1, 2021. InnerScope CEO Matthew Moore will provide viewers information about the company’s emerging and disruptive leadership in the “direct-to-consumer hearing technology” space. Moore explains his successful direct marketing strategy, helping people with access to the company’s hearing aids, which are selling at a fraction of the cost of those sold by…

Continue Reading

MondayNov 01, 2021 1:34 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has begun a new study, EPIL-A21-1,designed to evaluate whether its DehydraTECH(TM)-CBD (“CBD”) indicates superior ability to reduce seizure activity compared to both generic cannabidiol and Epidiolex. Epidiolex is the only CBD medication approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two rare and severe forms of pediatric epilepsy. Among those involved in the study are respirology and neurobiology experts. According to the announcement, the team of investigators will carefully analyze how DehydraTECH-CBD compares with Epidiolex in treating seizures.…

Continue Reading